Olli Kärkkäinen1, Mehdi Farokhnia2,3, Anton Klåvus4, Seppo Auriola1, Marko Lehtonen1, Sara L Deschaine2, Daria Piacentino2,5, Kelly M Abshire2, Shelley N Jackson6, Lorenzo Leggio2,5,6,7,8,9,10. 1. School of Pharmacy, University of Eastern Finland, Kuopio, Finland. 2. Clinical Psychoneuroendocrinology and Neuropsychopharmacology Section, Translational Addiction Medicine Branch, National Institute on Drug Abuse Intramural Research Program and National Institute on Alcohol Abuse and Alcoholism Division of Intramural Clinical and Biological Research, Baltimore and Bethesda, Maryland, USA. 3. Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA. 4. Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio, Finland. 5. Center on Compulsive Behaviors, National Institutes of Health, Bethesda, Maryland, USA. 6. Translational Analytical Core, National Institute on Drug Abuse Intramural Research Program, Baltimore, Maryland, USA. 7. Medication Development Program, National Institute on Drug Abuse Intramural Research Program, National Institutes of Health, Baltimore, Maryland, USA. 8. Center for Alcohol and Addiction Studies, Department of Behavioral and Social Sciences, Brown University, Providence, Rhode Island, USA. 9. Division of Addiction Medicine, Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA. 10. Department of Neuroscience, Georgetown University Medical Center, Washington, District of Columbia, USA.
Abstract
BACKGROUND: Ghrelin may influence several alcohol-related behaviors in animals and humans by modulating central and/or peripheral biological pathways. The aim of this exploratory analysis was to investigate associations between ghrelin administration and the human circulating metabolome during alcohol exposure in nontreatment seeking, heavy drinking individuals with alcohol use disorder (AUD). METHODS: We used serum samples from a randomized, crossover, double-blind, placebo-controlled human laboratory study with intravenous (IV) ghrelin or placebo infusion in two experiments. During each session, participants received a loading dose (3 µg/kg) followed by continuous infusion (16.9 ng/kg/min) of acyl ghrelin or placebo. The first experiment included an IV alcohol self-administration (IV-ASA) session and the second experiment included an IV alcohol clamp (IV-AC) session, both with the counterbalanced infusion of ghrelin or placebo. Serum metabolite profiles were analyzed from repeated blood samples collected during each session. RESULTS: In both experiments, ghrelin infusion was associated with an altered serum metabolite profile, including significantly increased levels of cortisol (IV-ASA q-value = 0.0003 and IV-AC q < 0.0001), corticosterone (IV-ASA q = 0.0202 and IV-AC q < 0.0001), and glycochenodeoxycholic acid (IV-ASA q = 0.0375 and IV-AC q = 0.0013). In the IV-ASA experiment, ghrelin infusion increased levels of cortisone (q = 0.0352) and fatty acids 18:1 (q = 0.0406) and 18:3 (q = 0.0320). Moreover, in the IV-AC experiment, ghrelin infusion significantly increased levels of glycocholic acid (q < 0.0001) and phenylalanine (q = 0.0458). CONCLUSION: IV ghrelin infusion, combined with IV alcohol administration, was associated with increases in the circulating metabolite levels of corticosteroids and glycine-conjugated bile acids, among other changes. Further research is needed to understand the role that metabolomic changes play in the complex interaction between ghrelin and alcohol.
BACKGROUND: Ghrelin may influence several alcohol-related behaviors in animals and humans by modulating central and/or peripheral biological pathways. The aim of this exploratory analysis was to investigate associations between ghrelin administration and the human circulating metabolome during alcohol exposure in nontreatment seeking, heavy drinking individuals with alcohol use disorder (AUD). METHODS: We used serum samples from a randomized, crossover, double-blind, placebo-controlled human laboratory study with intravenous (IV) ghrelin or placebo infusion in two experiments. During each session, participants received a loading dose (3 µg/kg) followed by continuous infusion (16.9 ng/kg/min) of acyl ghrelin or placebo. The first experiment included an IV alcohol self-administration (IV-ASA) session and the second experiment included an IV alcohol clamp (IV-AC) session, both with the counterbalanced infusion of ghrelin or placebo. Serum metabolite profiles were analyzed from repeated blood samples collected during each session. RESULTS: In both experiments, ghrelin infusion was associated with an altered serum metabolite profile, including significantly increased levels of cortisol (IV-ASA q-value = 0.0003 and IV-AC q < 0.0001), corticosterone (IV-ASA q = 0.0202 and IV-AC q < 0.0001), and glycochenodeoxycholic acid (IV-ASA q = 0.0375 and IV-AC q = 0.0013). In the IV-ASA experiment, ghrelin infusion increased levels of cortisone (q = 0.0352) and fatty acids 18:1 (q = 0.0406) and 18:3 (q = 0.0320). Moreover, in the IV-AC experiment, ghrelin infusion significantly increased levels of glycocholic acid (q < 0.0001) and phenylalanine (q = 0.0458). CONCLUSION: IV ghrelin infusion, combined with IV alcohol administration, was associated with increases in the circulating metabolite levels of corticosteroids and glycine-conjugated bile acids, among other changes. Further research is needed to understand the role that metabolomic changes play in the complex interaction between ghrelin and alcohol.
Authors: X M Guan; H Yu; O C Palyha; K K McKee; S D Feighner; D J Sirinathsinghji; R G Smith; L H Van der Ploeg; A D Howard Journal: Brain Res Mol Brain Res Date: 1997-08
Authors: Robin D Clugston; Hongfeng Jiang; Man Xia Lee; Roseann Piantedosi; Jason J Yuen; Rajasekhar Ramakrishnan; Michael J Lewis; Max E Gottesman; Li-Shin Huang; Ira J Goldberg; Paul D Berk; William S Blaner Journal: J Lipid Res Date: 2011-08-19 Impact factor: 5.922
Authors: Anni I Lehikoinen; Olli K Kärkkäinen; Marko A S Lehtonen; Seppo O K Auriola; Kati J Hanhineva; Seppo T Heinonen Journal: Eur J Obstet Gynecol Reprod Biol Date: 2018-02-17 Impact factor: 2.435
Authors: Lloyd W Sumner; Alexander Amberg; Dave Barrett; Michael H Beale; Richard Beger; Clare A Daykin; Teresa W-M Fan; Oliver Fiehn; Royston Goodacre; Julian L Griffin; Thomas Hankemeier; Nigel Hardy; James Harnly; Richard Higashi; Joachim Kopka; Andrew N Lane; John C Lindon; Philip Marriott; Andrew W Nicholls; Michael D Reily; John J Thaden; Mark R Viant Journal: Metabolomics Date: 2007-09 Impact factor: 4.290
Authors: Alice Zhang; Julianne L Price; David Leonard; Carol S North; Alina Suris; Martin A Javors; Bryon Adinoff Journal: Alcohol Clin Exp Res Date: 2020-06-03 Impact factor: 3.455